Browsing Biomedical Research Center Research by Publisher "BioMed Central"
Now showing items 1-11 of 11
-
Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA)
( BioMed Central , 2016 , Article)Intra-abdominal infections (IAI) are an important cause of morbidity and are frequently associated with poor prognosis, particularly in high-risk patients. The cornerstones in the management of complicated IAIs are timely ... -
Assessing the burden of intestinal parasites affecting newly arrived immigrants in Qatar
( BioMed Central , 2016 , Article)In the last decades, the enormous influx of immigrants to industrialized countries has led to outbreaks of parasitic diseases, with enteric infections being amongst the most frequently encountered. In its strategy to control ... -
Comparison of intestinal parasitic infection in newly arrived and resident workers in Qatar.
( BioMed Central , 2011 , Article)The rapid growth of Qatar in the last two decades has been associated with an enormous expansion of building programs in its cities and in the provision of new service industries. This in turn has attracted a large influx ... -
Coproscopy and molecular screening for detection of intestinal protozoa
( BioMed Central , 2017 , Article)Intestinal parasitosis is one of several health concerns about immigrants who travel from endemic to non-endemic regions. Reliable rapid sensitive diagnostic tools, for use in non-endemic regions, are urgently required to ... -
Helminth infections among long-term residents and settled immigrants in Qatar in the decade from 2005 to 2014: temporal trends and varying prevalence among subjects from different regional origins
( BioMed Central , 2016 , Article)Background: Travel and migration from developing regions, where tropical diseases are common, to more developed industrialised nations can contribute to the introduction and subsequent spread of infections. With its rapidly ... -
Molecular characterization of extended spectrum β -lactamases enterobacteriaceae causing lower urinary tract infection among pediatric population.
( BioMed Central , 2018 , Article)The β-lactam antibiotics have traditionally been the main treatment of Enterobacteriaceae infections, nonetheless, the emergence of species producing β- Lactamases has rendered this class of antibiotics largely ineffective. ... -
Prevalence of anelloviruses (TTV, TTMDV, and TTMV) in healthy blood donors and in patients infected with HBV or HCV in Qatar
( BioMed Central , 2016 , Article)Background Anelloviruses (TTV, TTMV, and TTMDV) have been associated with non A-G hepatitis. The goal of the current study was to estimate the prevalence of these anelloviruses in Qatar. Methods A total of 607 blood ... -
Prevalence of antibiotic resistant Escherichia coli isolates from fecal samples of food handlers in Qatar
( BioMed Central , 2018 , Article)Background: It is well documented that food handlers harbor and shed enteric foodborne pathogens causing foodborne disease outbreaks. However, little known on enteric antibiotic resistant (AR) bacteria carriage in ... -
The Qatar Biobank: background and methods
( BioMed Central , 2015 , Article)Background: The Qatar Biobank aims to collect extensive lifestyle, clinical, and biological information from up to 60,000 men and women Qatari nationals and long-term residents (individuals living in the country for ≥15 ... -
Seroprevalence of Toxoplasma gondii infection in feral cats in Qatar
( BioMed Central , 2017 , Article)Background: Cats are essential in the life cycle of Toxoplasma gondii as they can shed the environmentally resistant oocysts after acquiring infection. Human populations living in cities with high densities of feral cats ... -
VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma.
( BioMed Central , 2018 , Article)Vascular endothelial growth factor (VEGF) isoforms, particularly the diffusible VEGF-121, could play a major role in the response of recurrent glioblastoma (GB) to anti-angiogenetic treatment with bevacizumab. We hypothesized ...
